Abstract | INTRODUCTION: CASE REPORT: DISCUSSION: CONCLUSION: The use of modulators of angiogenesis such as bevacizumab is a possible therapeutic target in HHT.
|
Authors | H Bennesser Alaoui, M Lehraiki, S Hamaz, N El Attar, N Fakhreddine, K Serraj |
Journal | La Revue de medecine interne
(Rev Med Interne)
Vol. 36
Issue 9
Pg. 623-5
(Sep 2015)
ISSN: 1768-3122 [Electronic] France |
Vernacular Title | Bevacizumab : un nouveau succès dans la maladie de Rendu-Osler. |
PMID | 25595875
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Copyright | Copyright © 2014 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved. |
Chemical References |
|
Topics |
- Aged
- Anemia, Iron-Deficiency
(etiology, therapy)
- Bevacizumab
(therapeutic use)
- Blood Transfusion
- Humans
- Male
- Telangiectasia, Hereditary Hemorrhagic
(complications, therapy)
- Treatment Outcome
|